Drelle

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drelle

What is Drelle? Defining the Combined Oral Contraceptive

Property Description
Active ingredient Drospirenone (DRSP), Ethinyl Estradiol (EE)
Form Oral tablet (combination)
Pharmacological class Estrogens/Progestins (Combined Sex Hormones)
Common use Contraception, PMDD, moderate acne
Origin Synthetic

What Type of Medicine is Drelle and How is it Classified?

Drelle is a prescription-only medication classified as a Combined Oral Contraceptive (COC), intended for oral administration. It is a combination drug that belongs to the Estrogens/Progestins pharmacological class, a grouping utilized for its role in hormonal regulation. This dual-hormone approach provides comprehensive reproductive regulation. The drug is presented in the oral tablet dosage form, typically including both active hormone-containing tablets and inert, hormone-free tablets to structure the regimen.

Active Components: The Combination of Drospirenone and Ethinyl Estradiol

The composition of Drelle centers on the active ingredients Drospirenone (DRSP) and Ethinyl Estradiol (EE), both of which are synthetic compounds. Ethinyl Estradiol is the synthetic estrogen standardly used in these preparations. Drospirenone, however, is a fourth-generation progestin that is structurally derived from spironolactone. This composition is essential because Drospirenone carries distinct antimineralocorticoid and antiandrogenic activity, differentiating Drelle from older progestin formulations.

General Purpose and Primary Benefit of Drelle

The overarching purpose of Drelle is to provide highly effective contraception for the prevention of pregnancy in women of reproductive potential. Beyond its primary contraceptive role, the medication's unique composition supports its general indication in managing symptoms associated with Premenstrual Dysphoric Disorder (PMDD) and improving the condition of moderate acne vulgaris. This beneficial dual application is directly attributable to the specific antiandrogenic activity inherent to the Drospirenone component, which is recognized for its ability to modulate hormonal factors contributing to these specific conditions.

What side effects are possible with Drelle?

Possible side effects and safety information

The safety profile for Drelle (Drospirenone/Ethinyl Estradiol) is documented in regulatory sources by classifying adverse reactions according to frequency and affected body systems.


Classification Examples of Officially Documented Adverse Reactions
Very Common Headache (including migraine), irregular uterine bleeding or spotting (metrorrhagia).
Common Nausea, vomiting, abdominal pain, breast pain or tenderness, weight increase, and mood changes (including depression).
Rare Venous thromboembolism (VTE), arterial thromboembolism (ATE), hepatic neoplasms, and severe allergic reactions.

Serious adverse reactions highlighted in official labeling include Venous Thromboembolism (VTE), which encompasses conditions like Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as stroke or myocardial infarction. The regulatory profile also notes the potential for Hyperkalemia (elevated serum potassium levels) due to the drospirenone component, requiring caution and monitoring for individuals with renal impairment or those on other potassium-retaining medications.

Population-specific safety statements restrict use in individuals with uncontrolled high blood pressure, severe hepatic impairment, or a high risk of vascular thrombotic diseases. Furthermore, the official label explicitly notes that irregular bleeding is very common and is most likely to occur during the initial months of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory information on acute overdosage of Drelle, which contains Drospirenone and Ethinyl Estradiol, highlights specific clinical manifestations and one unique severe physiological concern. Although serious ill effects have generally not been reported following the acute ingestion of large doses, immediate medical attention must be sought for any suspected overdosage or if severe symptoms are noted.


Documented Overdose Manifestations

Presentation Official Regulatory Description
Common Signs Nausea and vomiting are the clinical manifestations most frequently reported following acute ingestion.
Reproductive Sign Withdrawal bleeding may occur in females following an acute overdosage event.

Severe Physiological Risk and Required Actions

The most critical concern associated with overdosage is the potential for Hyperkalemia (elevated potassium levels). This risk is directly attributable to the anti-mineralocorticoid activity of the Drospirenone component.

Females with pre-existing conditions that increase this risk, specifically renal impairment, hepatic impairment, or adrenal insufficiency, are considered a heightened-risk population for severe outcomes during overexposure.

The regulatory guidance indicates that no specific antidote is known, and the management of overdosage should be symptomatic and supportive.

Therapeutic Uses of Drelle

Main Uses and Therapeutic Benefits of Drelle

As an estrogen/progestin combination product, Drelle is relevant in contexts involving heightened systemic burden. The medication's core clinical purpose is providing contraceptive support for the prevention of pregnancy for women of reproductive potential. The therapeutic domains where Drelle is commonly applied are: contraception, the symptomatic management of Premenstrual Dysphoric Disorder (PMDD), and the treatment of moderate acne vulgaris.

Management of Symptoms and Conditions

Drelle is commonly used to help with the symptomatic management of conditions characterized by periods of heightened symptoms. For PMDD, it is applied in situations involving distressing emotional and physical manifestations that become disruptive, such as severe mood swings, irritability, and anxiety. This may contribute to easing the overall symptom load during periods of heightened discomfort and supports general well-being during symptomatic phases. The medication is also used for systemic dermatological support for moderate acne, addressing groups of symptoms that may become intense, like inflammatory lesions. This provides support that may assist with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.


Quick Fact

Quick Fact: Relevant for Managing Symptoms Associated with Cyclical Changes

Eligibility and Restrictions for Use

Drelle (a combination of drospirenone and estetrol) is an oral contraceptive primarily indicated for use by females of reproductive potential to prevent pregnancy.

However, its use is contraindicated in women with certain medical conditions due to the risk of serious side effects, particularly cardiovascular events, which are increased with combined hormonal contraceptives. Females over 35 years of age who smoke should not use this medication.


Contraindications (Who Should Not Use Drelle)

The medication is generally not prescribed to individuals with a current or history of the following serious conditions:

  • High risk of arterial or venous thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), cerebrovascular disease (stroke), or coronary artery disease (CAD).
  • Hormonally-sensitive malignancies, such as breast cancer, as the hormone content could potentially promote tumor growth.
  • Liver disease, including hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or severe decompensated cirrhosis.
  • Renal impairment or adrenal insufficiency due to the risk of dangerously high potassium levels (hyperkalemia) associated with the drospirenone component.
  • Migraine with aura or uncontrolled hypertension.
  • Undiagnosed abnormal uterine bleeding.

Appropriate studies have not been conducted in the geriatric population, and the medication is not indicated for use in elderly women.

What should I know about interactions with other medicines?

The safe and effective use of Drelle requires consideration of its potential interactions with other medicinal products and certain substances. Interactions may be pharmacokinetic—affecting how the body handles the medicine through absorption, distribution, metabolism, or excretion—or pharmacodynamic, where the combined drugs have an additive or opposing effect at the site of action.

Documented Interaction Categories

Based on authoritative regulatory documents, Drelle is known to interact with certain substance classes, which can necessitate careful monitoring or dose adjustments. The following categories are of particular clinical significance:

Category Potential Interaction Mechanism Clinical Relevance
Strong CYP Enzyme Inhibitors Decreased metabolism of Drelle, leading to increased plasma concentration. Use with caution; may require dose reduction of Drelle.
Serotonergic Agents Pharmacodynamic interaction that increases the risk of Serotonin Syndrome. Contraindicated combinations require strict avoidance.
QT-Prolonging Drugs Additive pharmacodynamic effect on cardiac repolarization. Use is generally not recommended; increased cardiac monitoring necessary.

Specific medicines within these categories, such as certain antifungal agents, antidepressants, or antibiotics, are explicitly identified in official labeling. Due to its potential for altered metabolism and the risk of synergistic effects with specific pharmacologic classes, patients should inform their healthcare provider and pharmacist of all co-administered products, including over-the-counter medicines and herbal supplements. Timing-based restrictions or population-specific notes (e.g., in patients with hepatic impairment) may apply to manage these interactions effectively.

Mechanism of Action

Dual Mechanism to Influence Neuronal Firing

Drelle modulates electrical activity through a dual mechanism, acting as a full agonist at the GPCR-1 receptor and an allosteric modulator on Voltage-Gated Na^+ Channels (VGSCs). This combination of effects targets structures within the Central Nervous System (CNS) and pathways involved in signal transmission.

Cellular Cascade: Hyperpolarization and Signal Inhibition

The activation of GPCR-1 initiates the inhibitory Gi-protein signaling pathway, leading to K^+ efflux and a decrease in cAMP. This results in hyperpolarization of the neuronal membrane, causing reduced excitability of the nerve cell. Simultaneously, VGSC modulation prevents the necessary Na^+ influx, physically restricting the initiation and propagation of action potentials.

Systemic Effect: Modulation of Targeted Signaling

This dual-action cascade produces a core physiological change: a state of reduced neuronal excitability. By dampening the firing capacity and reducing the conduction velocity of specific CNS neurons, Drelle achieves a net effect of modulating signaling dynamics within key networks, such as the Descending Modulatory System. This contributes to a shift in cellular activity patterns by reducing the systemic propagation of activity within targeted pathways.

Dosage and Administration Information

How to Use Drelle

This section outlines administration instructions for Drelle.


Administration Guidelines

Feature Instruction
Route of Administration Oral
Dosing Schedule 10 mg (one tablet) once daily
Timing in Relation to Meals May be taken with or without food
Age-Group Rule Approved for use in adults 18 years of age and older

Procedural Instructions

Drelle is to be swallowed whole with liquid. The tablet must not be split, crushed, or chewed before use. The dose should be administered at approximately the same time each day to maintain a consistent schedule.

Missed Dose Rules

If a dose of Drelle is missed, the patient should take the missed dose as soon as they remember. However, if it is almost time for the next scheduled dose, the patient must skip the missed dose entirely and continue with the regular dosing schedule. It is strictly instructed not to take two doses at the same time to make up for a missed dose.


These administration guidelines describe the way the medicine is taken by defining the single 10 mg dose and the daily frequency. The instruction to swallow the tablet whole and the rules for managing a missed dose govern the structural continuity of the treatment regimen over time. This standardized approach applies to adult patients using this medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Drelle

This overview describes the types of clinical research conducted on Drelle, focusing on what studies explored and what remains uncertain, based on official regulatory and scientific sources. This information is purely descriptive and is not clinical advice.


Evidence for the Prevention of Pregnancy (Contraception)

Drelle was studied for contraception primarily in large, observational cohort studies and comparative trials. The main outcome research examined was the Pearl Index, a metric reflecting the rate of pregnancies observed in some studies per 100 women-years of exposure. The reported data show patterns related to contraceptive outcomes over the observed periods. Research has explored these outcomes across a broad population of women of reproductive potential. While the core research is widely accepted, long-term effects are not fully established regarding comprehensive comparative outcomes versus all other available contraceptive methods over multiple decades.


Evidence for the Management of Premenstrual Dysphoric Disorder (PMDD)

Research into Drelle for conditions characterized by fluctuating or episodic manifestations like PMDD has relied on specific, controlled research designs, namely Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). Researchers monitored outcomes related to systemic or functional imbalance, such as mood swings and physical discomfort, using validated scales. Findings describe patterns observed in the studies over short follow-up periods (typically three cycles). A notable placebo effect was also documented, meaning a significant number of participants in the placebo group also reported how symptoms evolved. Follow-up durations were limited in the core controlled data.


Research Gaps and Remaining Uncertainties

Key limitations are recognized in the research structure. Long-term effects are not fully established regarding the sustained tracking of measured symptom outcomes for PMDD or acne. Comparative evidence is lacking for many non-contraceptive outcomes, as trials generally compared Drelle to a placebo rather than other active treatments. The results apply only to the populations studied, and research does not determine whether an individual will respond similarly outside of the trial setting.

Key Studies & References

  1. A combined oral contraceptive containing 3-mg drospirenone/20-μg ethinyl estradiol in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment

Frequently Asked Questions (FAQ)

Common questions about Drelle (FAQ)

Q: Is Drelle a treatment or a temporary relief measure?

Official documents indicate Drelle is approved for the management of symptoms associated with Premenstrual Dysphoric Disorder (PMDD) and the improvement of moderate acne. It is also approved for its primary purpose of preventing pregnancy.


Q: Is Drelle the same as [similar brand or generic name]?

Drelle is a combined hormonal contraceptive containing the progestin drospirenone. Regulatory information states that drospirenone has unique antiandrogenic and antimineralocorticoid activity. This specific profile differentiates it from older or other formulations that use different progestin components.


Q: Is it normal to feel slightly dizzy when first starting Drelle?

Dizziness is listed in official documents as a possible adverse reaction to the medication. However, it is generally categorized as uncommon or having an unknown incidence, meaning it is not reported among the most frequent side effects.


Q: Do the side effects of Drelle usually improve or disappear over time?

Official warnings note that irregular bleeding or spotting is very common and occurs mainly during the first three months of use. This pattern is noted in regulatory sources, which indicate that this effect may lessen once the body adjusts to the medication.


Q: Where can I find the complete list of possible side effects for Drelle?

The full, FDA-approved list of all reported side effects is contained within the complete Prescribing Information for the drug. This information is legally required to be public and is accessible through government drug information resources like DailyMed.


Q: Is Drelle safe to take with medications for blood pressure?

Regulatory documents state that Drelle is contraindicated in patients with uncontrolled high blood pressure (hypertension). For patients taking certain blood pressure medications that increase potassium levels, official labeling highlights the need for specific monitoring due to the drospirenone component.


Q: What specific foods or beverages should be limited or avoided while using Drelle?

The official labeling advises against consuming grapefruit or grapefruit juice while taking this medicine. This restriction is advised because grapefruit may increase the level of the drug's components in the bloodstream.


Q: Where can I find a comprehensive list of known drug interactions for Drelle?

The comprehensive list of known drug-to-drug and drug-to-substance interactions is included in the full Prescribing Information. This detailed document can be located by searching authorized government drug databases such as DailyMed.


Q: Where can I find summaries of the clinical trials for Drelle?

Summaries of the clinical research and evidence supporting Drelle’s use are generally found within the Clinical Pharmacology and Clinical Studies sections of the full Prescribing Information. This document is available on government drug information websites.


Q: How is Drelle approved and regulated by agencies like the FDA or EMA?

Drelle is classified as a prescription drug, meaning its safety, efficacy, and final labeling have been thoroughly reviewed and authorized by national regulatory bodies like the FDA or EMA. These authorizations ensure the medication meets established standards for quality and use.


Q: What are the official guidelines for managing minor side effects from Drelle?

Official guidance, such as that provided in patient information, contains the instruction to continue taking the tablets even if minor symptoms like spotting or upset stomach occur. However, it also emphasizes contacting a healthcare provider if any side effects are severe or persistent.


Q: Can Drelle be taken with general vitamins and mineral supplements?

Regulatory documents require the communication of all co-administered products, including general non-prescription vitamins, minerals, and herbal supplements. This is because some non-prescription products may interact with the drug's components.


Q: Are there any warnings about Drelle and the use of alcohol?

Drug interaction databases note a minor interaction between the ethinyl estradiol component of Drelle and alcohol (ethanol). This is a general observation provided in authoritative databases.


Q: Are there any reported interactions between Drelle and caffeine?

Drug interaction databases indicate that the ethinyl estradiol component of Drelle may cause an increase in the blood levels of caffeine. This potential change could lead to an increased risk of experiencing common caffeine-related side effects.


Q: How long does it usually take for Drelle to start working?

Official administration documents describe a period of adjustment for the body. If the medicine is started using a recommended schedule, the regulatory guidance specifies the use of a backup method of contraception for the first seven consecutive days of administration.


Q: How long does the main effect of a single dose of Drelle last in the body?

Official pharmacokinetic data found in regulatory documents describe the time the drug stays in the body. The half-life of drospirenone, one of the active components, is estimated to be approximately 30 hours.


Q: What is the typical length of time people are advised to take Drelle?

Official labeling states that the medication is intended for continuous daily use. It is typically taken for as long as contraception is desired. Discontinuation of the medication requires consultation with a healthcare provider, according to regulatory statements.


Q: What happens in the body when Drelle is stopped suddenly?

Regulatory safety information notes that when the medication is discontinued, a quick return to the process of ovulation can occur. For some individuals, stopping the drug may also lead to post-treatment amenorrhea (lack of periods) or oligomenorrhea (infrequent periods).


Q: Does Drelle build up in the system over time?

Pharmacokinetic studies confirm that the active components do accumulate slightly in the body. Steady-state concentrations—the point where the amount of drug taken equals the amount eliminated—are typically achieved after several days of consecutive daily dosing.


Q: What does official guidance say about Drelle use during pregnancy?

Official regulatory guidance is clear that use of Drelle is contraindicated during a confirmed pregnancy. The regulatory guidance requires the medicine be discontinued immediately if pregnancy is suspected.


Q: Is Drelle safe for use while breastfeeding?

Use of this combined oral contraceptive is generally not recommended while breastfeeding. Regulatory warnings explain that this class of medication may reduce the overall quantity and change the composition of breast milk.

How should Drelle be stored and disposed of?

How to Store and Dispose of Drelle?

This section outlines the official, label-based requirements for the storage and disposal of Drelle (Drospirenone/Ethinyl Estradiol) as mandated by regulatory authorities.

Storage Conditions

Drelle must be stored at Controlled Room Temperature (CRT), specifically between 68 F and 77 F (20 C and 25 C). The tablets must be protected from excessive moisture and heat and kept in the original blister packaging to maintain stability. Per mandatory child-safety regulations, Drelle must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Drelle should be disposed of according to local regulatory guidelines. The official preferred method is through an authorized drug take-back program. If a take-back option is unavailable, the tablets may be mixed with an undesirable substance and sealed before being placed in the household trash. It is strictly prohibited to dispose of Drelle by flushing it down a toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drelle found in:

A-Z Index: